Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Western Europe VC Firm Specializes in Oncology Drug Development Companies, Investing Up to $10M in USA & Europe Technologies

14 Oct

A venture capital firm based in Western Europe is entirely specialized in and focused on investing in early-stage oncology drug development companies. For its most recent fund, the firm seeks to invest in an estimated 10 biotechnology start-ups in cancer treatment. Typical investments are made in equity and with an average ticket size of 10 million Euros over a period of 5 to 7 years. In addition, the firm seeks to invest 1-2 million Euros in promising academic cancer research projects over a period of 18 months with the aim to transition these projects to NewCo’s. The firm seeks a lead investor role in companies based in the Netherlands and Belgium, and a co-investor role in other regions. The firm prefers syndicated investments with like-minded investors with equal ticket sizes. The firm’s main focus is on European companies, although they will consider US opportunities.

The firm focuses on a wide spectrum of cancer treatment, including but not limited to small molecules, antibodies, gene therapy, cell therapy, and immunotherapy. The firm supports early-stage companies from incubator stage and preclinical through phase 1. The firm prefers to invest in companies that have underlying platform technologies.

The firm can support management teams by being operationally involved on an interim basis in companies based in the country of their headquarters, and will frequently set-up companies from scratch with the inventors. The firm can help refine the business plan, R&D plans and provide financial, IP, IT, legal, HR support. If needed, the firm will take up interim-management roles.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Single Family Office Invests in Series A and Later Financing Rounds, Interested in Pre-Clinical Therapeutics, Devices, and Diagnostics

14 Oct

A USA-based single family office is very flexible in terms of investment size they are generally looking to invest a minimum of $.5 million per round, depending upon size of round and estimated capital call. The firm prefers A round and later stage companies. Pre-A interest depends upon technology stage. The firm’s preferred geography is North America and Europe.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. The firm invests on an opportunistic basis in areas of intersecting technologies, such as nucleic acid-based drugs and delivery, regenerative medicine and cell-based therapeutics and other immune-directed  therapies. The firm generally will not consider single target small molecules, biosimilars or other technologies for which there is already multiple therapeutic options. The firm is looking for niche disease areas where disruptive therapeutics have the potential to be truly disease-modifying, not just provide symptomatic relief or palliative care. The firm typically is interested in preclinical stage assets that have well-developed animal model dossiers to Phase II or early Phase III stage assets.

 The firm’s investment mandate particularly focuses on “smart” clinical trial formats such as adaptive trials and Master Protocol trials for capital efficiency. For devices, the firm is looking for devices that address and perhaps substitute for a pharmacologic in a given therapeutic market, such as deep brain stimulation technologies and orthopedics. The firm is generally not interested in cardiovascular disease or diabetes.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Healthcare-Focused VC Firm in USA Invests Globally in Therapeutics, Devices, Diagnostics, Digital Health, with Opportunistic Outlook

14 Oct

An early stage healthcare focused venture capital firm headquartered in the East Coast USA invests in Pre-Seed, Seed and Series A rounds across all four life science sectors. The firm has a current fund of $50M that they are actively raising and investing out of. The typical check size ranges from $100K – $1.5M in the form of priced rounds, equity, SAFEs or convertible notes. The firm invests globally, with a focus on helping companies outside of the US get into the US market.

The firm seeks to make investments in all four life science sectors, and is agnostic to subsector and indication. The firm is looking to provide start-ups with capital as well as advisory and strategic input when needed. The firm is open to pre-clinical companies and is open to all three classes of medical devices.

The firm is open to all types of management teams including first time entrepreneurs and underrepresented groups. The firm likes to typically lead investments, and will seek a board seat, but is also open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot AI Mandate: US-based VC

12 Oct

A venture capital company was founded in 2007 and based in Durham, North Carolina with additional office in Orlando, Florida. The firm has approximately $38 million in total assets under management. The firm seeks to make equity investments in 2 to 3 companies in the next 6 to 9 months. The average first investment in a company is $0.1 million to $ 0.75 million, though it can invest up to $ 1.5 million, depending on the opportunity. The firm prefers to invest in seed and early- stage companies located in the Southeast and Mid-Atlantic regions of the US with a focus in the states of North Carolina and Florida.

The firm is currently looking for new investment opportunities in Medical Technology and Healthcare IT spaces. The firm is most interested in companies producing medical devices and software. The firm is very opportunistic in terms of medical devices, and it would consider companies operating within any subsector of medical technology. The firm generally makes investments in pre-clinical and prototype stages within medical technology sector.

The firm will consider pre-revenue companies and make initial investments in companies with no revenues. The firm prefers to invest in technologies that are disruptive to existing markets or enable entirely new ones. The firm will not consider any biotechnology and pharmaceutical companies, and additionally would not be interested in growth companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: US and Japan-based VC

12 Oct

Based in San Francisco, CA, and has an additional office in Japan, a venture capital firm is investing from a new fund that closed in 2016. The firm generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 70% of its capital in the USA and Israel, with the remaining 30% in Japan. Under certain circumstances, the firm will invest outside those regions. It has invested thus far in some well-known companies.

The firm invests in advanced therapeutics, healthcare IT, novel (sensor based IoT) devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. The firm prefers to invest in technologies at an early stage of development.

The firm is interested in working with high quality management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: CA-based VC

12 Oct

A venture capital firm based in Southern California is actively making early-stage investments in all sectors of healthcare. The firm is currently investing from their first fund, through which the firm will invest in 25-40 companies over the next 3-5 years. To date, the firm’s current portfolio includes over 25 companies. The firm’s typical size of initial investment is $100-500K in the form of equity, convertible note, among other monetary vehicles. The firm focuses on Seed to Series A-stage companies that are based in Southern California, but opportunistically invest across all of USA and the world.

The firm invests in medical device, diagnostics, and digital health companies, but will generally not invest in therapeutics or biopharmaceuticals. The firm is opportunistic and will consider all promising technologies within the aforementioned sectors.

The firm generally invests in companies with a pre-money valuation less than $10M, but is capable of participating in investments in larger companies. The firm likes to companies within 6 months of FDA clearance or approval, or revenue generation. The firm is open to working with small/inexperienced management teams and is agnostic with regards to management team requirements. The firm is an active investor who selectively serve on boards, and actively engages their LPs who have healthcare subject matter expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Longevity Mandate: Canada-Based Diagnostics Company

12 Oct

The company is Canada’s largest diagnostic lab and is the leading diagnostic testing facility for communities in Ontario and BC. The company does 120 million diagnostic tests a year in centralized labs and 450+ offices and patient service centers. The firm has made a number of acquisitions in the last 10 years, and consolidated lab testing by acquiring the largest competitive lab in Ontario and the only competitive lab in BC. The firm is looking solely for long term strategic partnerships with organizations that have technology in point of care testing and novel diagnostic testing as well as technology platforms. The company looks globally for opportunities.

The company is looking for strategic partnerships in both the medical device and diagnostic sectors. The firms main focus is point of care technologies, rapid testing, cardiovascular, wearables and biometrics, and the firm is open to all indications. The company also looks to women and men’s health, as well as novel mental health and brain related technologies. The firm is open to pre-clinical companies.

The company looks for management teams with deep subject matter expertise within their field and a strong track record. The firm is open to both co-investing or leading an investment, where they will seek board seat representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

%d bloggers like this: